Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.59 |
| ▸ | MMP8 | P22894 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344189 | 0.93 | MMP13 (0.59) | MMP13MMP8TSHRMAOAKDM4E | |
| SCHEMBL8189556 | 0.91 | MMP13 (0.62) | MMP13MMP8TSHRMAOAMAPT | |
| SCHEMBL13344440 | 0.90 | MMP13 (0.59) | MMP13MMP8TSHRMAOAMAPT | |
| SCHEMBL8189550 | 0.90 | MMP13 (0.61) | MMP13MMP8TSHRMAOAKDM4E | |
| SCHEMBL13344218 | 0.90 | MMP13 (0.62) | MMP13MMP8TSHRMAOAPARP1 | |
| SCHEMBL8198673 | 0.89 | MMP13 (0.62) | MMP13MMP8TSHRMAOAMAPT | |
| SCHEMBL13344220 | 0.89 | MMP13 (0.60) | MMP13MMP8TSHR | |
| SCHEMBL13369329 | 0.88 | MMP13 (0.59) | MMP13MMP8TSHRMAOAMAPT | |
| SCHEMBL8187445 | 0.88 | MMP13 (0.62) | MMP13MMP8TSHRMAOAMAPT | |
| SCHEMBL8197438 | 0.88 | MMP13 (0.62) | MMP13MMP8TSHRMAOAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885MMP8 5/4885TSHR 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.